📰 Allogeneic News
Page 2 - Allogeneic News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Allogeneic. Real-time updates on events, politics, business and more.
June 5, 2023
Single-Step CD45-Engager Strategy Generates Immune-Privileged Cells with Abrogation of Host Cellular Immune Responses Being Developed to Eliminate the Need for Complex, Expensive Gene-Editing Approaches
June 5, 2023
Preclinical data on UCART20x22, Cellectis’ first allogeneic dual CAR T-cell product candidate to treat B-NHL, presented at an oral session Encouraging data presented on gene editing process... | June 5, 2023
June 3, 2023
Long Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials Demonstrate Potential of Allogeneic CD19 CAR T to Generate Durable Complete Responses Similar to Approved Autologous Therapies Presentation... | June 3, 2023
June 1, 2023
Data published online in the journal Cytotherapy demonstrate that CRISPR-mediated tissue factor gene knockout in allogeneic stromal cells leads to significantly lower tissue factor expression,... | June 1, 2023
May 31, 2023
Azer-Cel Safety Profile was Significantly Improved Compared to Prior Cohorts in Patients Dosed Using Optimized Product at Lower Intensity Lymphodepletion; No Grade 3 or Greater Allogeneic CAR T... | May 31, 2023
May 31, 2023
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on May 31,... | May 31, 2023
May 30, 2023
New data from clinical trials of TT11 and TT11X to be featured in oral and poster presentationsSINGAPORE, May 30, 2023 (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments
May 24, 2023
SOUTH SAN FRANCISCO, Calif., May 24, 2023 -- Allogene Therapeutics, Inc. , a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products for cancer, today... | May 24, 2023
May 24, 2023
Precision BioSciences, Inc. a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced that the Company will... | May 24, 2023
May 22, 2023
Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported that the Company is expected to be added to the... | May 22, 2023